Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free CVAC Stock Alerts

CureVac (CVAC) Financials

CureVac logo
$4.66 0.00 (0.00%)
As of 05/6/2026
Compare
Annual Income Statements for CureVac

Annual Income Statements for CureVac

This table shows CureVac's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -82 -112 -158 -466 -266 -288 168
Consolidated Net Income / (Loss)		 -82 -112 -158 -466 -266 -288 168
Net Income / (Loss) Continuing Operations		 -82 -112 -158 -466 -266 -288 168
Total Pre-Tax Income 		-81 -112 -159 -467 -267 -288 198
Total Operating Income		 -83 -112 -159 -467 -267 -288 198
Total Gross Profit		 -5.58 -6.91 47 572 -85 -54 433
Total Revenue		 15 27 92 855 117 88 578
Operating Revenue		 - 27 92 855 117 88 578
Total Cost of Revenue		 20 34 45 283 202 142 145
Operating Cost of Revenue		 20 34 45 283 202 142 145
Total Operating Expenses		 78 105 205 1,039 181 234 235
Selling, General & Admin Expense		 29 57 66 116 114 106 77
Research & Development Expense		 48 49 139 923 67 128 158
Total Other Income / (Expense), net		 1.94 0.00 0.00 0.00 0.00 0.00 0.00
Income Tax Expense		 0.13 -0.28 -0.89 -0.89 -0.13 0.22 30
Basic Earnings per Share		 - ($1.03) ($0.98) ($2.21) ($1.41) ($1.31) $0.75
Weighted Average Basic Shares Outstanding		 - - 187.12M - 194.95M 223.99M 224.34M
Diluted Earnings per Share		 - ($1.03) ($0.98) ($2.21) ($1.41) ($1.31) $0.75
Weighted Average Diluted Shares Outstanding		 - - 187.12M - 194.95M 223.99M 224.34M
Weighted Average Basic & Diluted Shares Outstanding		 - - 187.12M - 194.95M 223.99M 224.34M

Quarterly Income Statements for CureVac

No quarterly income statements for CureVac are available.

Annual Cash Flow Statements for CureVac

This table details how cash moves in and out of CureVac's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -90 49 1,584 -584 -339 -102 81
Net Cash From Operating Activities		 -85 -3.74 638 -830 -306 -296 105
Net Cash From Continuing Operating Activities		 -78 -3.74 658 -932 -407 -367 86
Net Income / (Loss) Continuing Operations		 -81 0.00 -159 -467 -267 -288 198
Consolidated Net Income / (Loss)		 -81 - -159 -467 -267 -288 198
Non-Cash Adjustments To Reconcile Net Income		 -6.74 -0.65 48 -398 17 -0.66 27
Changes in Operating Assets and Liabilities, net		 5.36 -11 756 -85 -157 -104 -139
Net Cash From Investing Activities		 -4.88 53 -55 -145 -100 -61 -19
Net Cash From Continuing Investing Activities		 -17 53 -55 -145 -100 -61 -19
Purchase of Property, Plant & Equipment		 -17 - -58 -145 -100 -61 -19
Acquisitions		 - - 0.00 0.00 -0.30 0.00 0.00
Net Cash From Financing Activities		 -0.13 0.00 1,002 390 68 255 -5.29
Net Cash From Continuing Financing Activities		 -0.13 0.00 971 425 -4.52 255 -5.29
Repayment of Debt		 -0.13 - -119 -32 -4.52 -5.74 -5.29
Issuance of Common Equity		 0.00 0.00 1,060 457 0.00 261 0.00

Quarterly Cash Flow Statements for CureVac

No quarterly cash flow statements for CureVac are available.

Annual Balance Sheets for CureVac

This table presents CureVac's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2021 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 147 1,311 1,311 921 872 831
Total Current Assets		 64 1,064 1,064 625 529 545
Cash & Equivalents		 34 918 918 530 445 499
Accounts Receivable		 18 21 21 6.73 16 15
Inventories, net		 6.95 64 64 37 30 0.56
Prepaid Expenses		 1.89 56 56 43 26 17
Current Deferred & Refundable Income Taxes		 - - - 0.30 5.75 6.00
Other Current Assets		 - 0.00 - - - 2.86
Other Current Nonoperating Assets		 1.64 5.26 5.26 4.80 2.94 3.75
Plant, Property, & Equipment, net		 54 190 190 212 262 212
Plant, Property & Equipment, gross		 54 190 190 212 262 212
Total Noncurrent Assets		 28 57 57 84 81 74
Intangible Assets		 6.39 15 15 34 31 26
Noncurrent Deferred & Refundable Income Taxes		 0.00 3.24 3.24 1.39 1.32 5.27
Other Noncurrent Operating Assets		 22 38 38 49 48 43
Total Liabilities & Shareholders' Equity		 147 1,311 1,311 921 872 831
Total Liabilities		 195 532 532 350 300 110
Total Current Liabilities		 32 405 405 167 206 75
Accounts Payable		 7.27 145 145 79 53 18
Current Deferred & Payable Income Tax Liabilities		 0.12 0.84 0.84 0.65 0.72 19
Other Current Liabilities		 24 260 260 88 152 38
Total Noncurrent Liabilities		 163 127 127 183 94 35
Capital Lease Obligations		 14 29 29 40 41 35
Noncurrent Deferred & Payable Income Tax Liabilities		 1.82 - - - - 0.23
Other Noncurrent Operating Liabilities		 75 98 98 143 53 0.00
Total Equity & Noncontrolling Interests		 -48 779 779 570 572 721
Total Preferred & Common Equity		 -48 779 779 570 572 721
Total Common Equity		 -48 779 779 570 572 721
Common Stock		 13 25 25 25 30 28
Retained Earnings		 -579 -1,196 -1,196 -1,397 -1,732 -1,453
Accumulated Other Comprehensive Income / (Loss)		 0.02 -0.04 -0.04 -0.15 -0.07 0.04
Other Equity Adjustments		 518 1,956 1,956 1,944 2,274 2,146

Quarterly Balance Sheets for CureVac

No quarterly balance sheets for CureVac are available.

Annual Metrics And Ratios for CureVac

This table displays calculated financial ratios and metrics derived from CureVac's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 81.59% 242.92% 831.90% -86.31% -24.70% 555.77%
EBITDA Growth		 0.00% -32.02% -39.55% -208.49% 40.65% 1.82% 175.50%
EBIT Growth		 0.00% -34.82% -41.17% -194.32% 42.91% -7.89% 168.71%
NOPAT Growth		 0.00% -34.82% -41.17% -194.32% 42.91% -7.89% 183.40%
Net Income Growth		 0.00% -37.47% -40.73% -195.42% 42.83% -8.03% 158.33%
EPS Growth		 0.00% 0.00% 4.85% -125.51% 36.10% 7.56% 157.10%
Operating Cash Flow Growth		 0.00% 95.59% 17,145.78% -230.02% 63.10% 3.21% 135.58%
Free Cash Flow Firm Growth		 0.00% 0.00% 850.11% -252.53% 59.36% 22.92% 127.68%
Invested Capital Growth		 0.00% 0.00% -29,144.36% 83.87% 164.80% 119.34% 53.15%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 -37.86% -25.84% 50.93% 66.93% -72.80% -60.99% 74.90%
EBITDA Margin		 -536.42% -390.00% -158.71% -52.54% -227.83% -297.07% 34.20%
Operating Margin		 -565.80% -420.06% -172.92% -54.61% -227.83% -326.43% 34.20%
EBIT Margin		 -565.80% -420.06% -172.92% -54.61% -227.83% -326.43% 34.20%
Profit (Net Income) Margin		 -553.50% -419.00% -171.95% -54.51% -227.71% -326.68% 29.06%
Tax Burden Percent		 100.15% 99.75% 99.44% 99.81% 99.95% 100.08% 84.97%
Interest Burden Percent		 97.68% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.03%
Return on Invested Capital (ROIC)		 0.00% -6,371.59% 0.00% 0.00% 0.00% -168.17% 80.66%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -6,503.97% 0.00% 0.00% 0.00% -149.02% 80.66%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 6,838.27% 0.00% 0.00% 0.00% 117.79% -54.69%
Return on Equity (ROE)		 0.00% 466.67% -38.43% -56.54% -39.48% -50.39% 25.97%
Cash Return on Invested Capital (CROIC)		 0.00% -6,571.59% 0.00% 0.00% -503.20% -242.92% 38.67%
Operating Return on Assets (OROA)		 0.00% -76.65% -15.92% -29.57% -23.89% -32.09% 23.20%
Return on Assets (ROA)		 0.00% -76.46% -15.83% -29.52% -23.88% -32.11% 19.72%
Return on Common Equity (ROCE)		 0.00% 466.67% -38.43% -56.54% -39.48% -50.39% 25.97%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 233.34% -18.15% -59.80% -46.70% -50.33% 23.28%
Net Operating Profit after Tax (NOPAT)		 -58 -79 -111 -327 -187 -201 168
NOPAT Margin		 -396.06% -294.04% -121.04% -38.23% -159.48% -228.50% 29.06%
Net Nonoperating Expense Percent (NNEP)		 0.00% 132.37% -6.08% -11.22% -11.48% -19.16% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -30.58% -32.86% 22.21%
Cost of Revenue to Revenue		 137.86% 125.84% 49.07% 33.07% 172.80% 160.99% 25.10%
SG&A Expenses to Revenue		 196.48% 212.80% 72.29% 13.52% 97.84% 120.13% 13.28%
R&D to Revenue		 324.16% 181.41% 151.56% 108.02% 57.20% 145.31% 27.42%
Operating Expenses to Revenue		 529.07% 394.22% 223.86% 121.55% 155.03% 265.44% 40.70%
Earnings before Interest and Taxes (EBIT)		 -83 -112 -159 -467 -267 -288 198
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -104 -146 -449 -267 -262 198
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.24 7.95 1.98 1.44 1.06
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.27 8.10 2.10 1.52 1.10
Price to Revenue (P/Rev)		 14.48 7.98 11.78 7.24 9.64 9.32 1.32
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 4.55
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.98%
Enterprise Value to Invested Capital (EV/IC)		 0.00 107.52 0.00 0.00 8.51 2.53 1.19
Enterprise Value to Revenue (EV/Rev)		 0.00 9.92 0.00 6.20 5.45 4.73 0.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 1.52
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 1.52
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 1.79
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 2.85
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 3.73
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 -1.80 0.04 0.04 0.07 0.07 0.05
Long-Term Debt to Equity		 0.00 -1.80 0.04 0.04 0.07 0.07 0.05
Financial Leverage		 0.00 -1.05 -1.87 -1.51 -1.03 -0.79 -0.68
Leverage Ratio		 0.00 -3.05 2.43 1.92 1.65 1.57 1.32
Compound Leverage Factor		 0.00 -3.05 2.43 1.92 1.65 1.57 1.32
Debt to Total Capital		 0.00% 224.63% 3.64% 3.56% 6.51% 6.65% 4.61%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 224.63% 3.64% 3.56% 6.51% 6.65% 4.61%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -124.63% 96.36% 96.44% 93.49% 93.35% 95.39%
Debt to EBITDA		 0.00 -0.83 -0.23 -0.06 -0.15 -0.16 0.18
Net Debt to EBITDA		 0.00 -0.50 10.87 1.98 1.84 1.55 -2.35
Long-Term Debt to EBITDA		 0.00 -0.83 -0.23 -0.06 -0.15 -0.16 0.18
Debt to NOPAT		 0.00 -1.10 -0.30 -0.09 -0.21 -0.20 0.21
Net Debt to NOPAT		 0.00 -0.66 14.26 2.72 2.63 2.01 -2.76
Long-Term Debt to NOPAT		 0.00 -1.10 -0.30 -0.09 -0.21 -0.20 0.21
Altman Z-Score		 0.00 -6.95 0.74 5.79 -0.42 -1.68 3.88
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.04 5.61 2.63 3.74 2.57 7.28
Quick Ratio		 0.00 1.70 5.35 2.32 3.23 2.25 6.85
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -81 609 -928 -377 -291 80
Operating Cash Flow to CapEx		 -503.36% 0.00% 1,103.23% -573.20% -306.98% -485.30% 552.22%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -269.49 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -323.03 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.18 0.09 0.54 0.10 0.10 0.68
Accounts Receivable Turnover		 0.00 1.52 9.73 77.08 8.45 7.80 37.98
Inventory Turnover		 0.00 4.84 3.64 6.95 4.03 4.24 9.45
Fixed Asset Turnover		 0.00 0.50 1.36 6.29 0.58 0.37 2.44
Accounts Payable Turnover		 0.00 4.63 2.67 3.31 1.81 2.15 4.08
Days Sales Outstanding (DSO)		 0.00 240.26 37.50 4.74 43.17 46.78 9.61
Days Inventory Outstanding (DIO)		 0.00 75.41 100.18 52.50 90.66 86.18 38.61
Days Payable Outstanding (DPO)		 0.00 78.79 136.88 110.42 201.43 169.50 89.38
Cash Conversion Cycle (CCC)		 0.00 236.88 0.80 -53.19 -67.60 -36.54 -41.17
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 2.47 -717 -116 75 164 252
Invested Capital Turnover		 0.00 21.67 -0.26 -2.05 -5.75 0.74 2.78
Increase / (Decrease) in Invested Capital		 0.00 2.47 -720 601 191 89 87
Enterprise Value (EV)		 0.00 265 -502 5,302 638 416 300
Market Capitalization		 213 213 1,081 6,192 1,128 821 764
Book Value per Share		 $0.00 ($3.60) $4.64 $4.32 $3.05 $2.93 $3.22
Tangible Book Value per Share		 $0.00 ($4.08) $4.55 $4.23 $2.87 $2.77 $3.10
Total Capital		 0.00 39 902 808 610 613 756
Total Debt		 0.00 87 33 29 40 41 35
Total Long-Term Debt		 0.00 87 33 29 40 41 35
Net Debt		 0.00 52 -1,583 -890 -491 -404 -464
Capital Expenditures (CapEx)		 17 -43 58 145 100 61 19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.79 -220 -259 -73 -122 -29
Debt-free Net Working Capital (DFNWC)		 0.00 33 1,395 659 458 323 470
Net Working Capital (NWC)		 0.00 33 1,395 659 458 323 470
Net Nonoperating Expense (NNE)		 23 33 47 139 80 86 0.00
Net Nonoperating Obligations (NNO)		 0.00 51 -1,586 -895 -496 -407 -469
Total Depreciation and Amortization (D&A)		 4.33 8.04 13 18 0.00 26 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -6.69% -240.19% -30.34% -62.17% -138.70% -4.96%
Debt-free Net Working Capital to Revenue		 0.00% 122.04% 1,521.13% 77.09% 391.19% 366.64% 81.36%
Net Working Capital to Revenue		 0.00% 122.04% 1,521.13% 77.09% 391.19% 366.64% 81.36%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.18) $0.75
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 223.99M 224.34M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.18) $0.75
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 223.99M 224.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 223.99M 224.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -58 -79 -111 -327 -187 -201 168
Normalized NOPAT Margin		 -396.06% -294.04% -121.04% -38.23% -159.48% -228.50% 29.06%
Pre Tax Income Margin		 -552.65% -420.06% -172.92% -54.61% -227.83% -326.43% 34.20%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -264.81 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -185.37 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -318.35 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -238.91 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for CureVac

No quarterly metrics and ratios for CureVac are available.


Financials Breakdown Chart

Frequently Asked Questions About CureVac's Financials

When does CureVac's financial year end?

According to the most recent income statement we have on file, CureVac's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CureVac's net income changed over the last 6 years?

CureVac's net income appears to be on a downward trend, with a most recent value of $167.88 million in 2024, falling from -$81.54 million in 2018. The previous period was -$287.80 million in 2023. Find out what analysts predict for CureVac in the coming months.

What is CureVac's operating income?
CureVac's total operating income in 2024 was $197.58 million, based on the following breakdown:
  • Total Gross Profit: $432.73 million
  • Total Operating Expenses: $235.14 million
How has CureVac's revenue changed over the last 6 years?

Over the last 6 years, CureVac's total revenue changed from $14.73 million in 2018 to $577.72 million in 2024, a change of 3,821.8%.

How much debt does CureVac have?

CureVac's total liabilities were at $109.95 million at the end of 2024, a 63.4% decrease from 2023, and a 43.5% decrease since 2019.

How much cash does CureVac have?

In the past 5 years, CureVac's cash and equivalents has ranged from $34.44 million in 2019 to $918.41 million in 2020, and is currently $498.66 million as of their latest financial filing in 2024.

How has CureVac's book value per share changed over the last 6 years?

Over the last 6 years, CureVac's book value per share changed from 0.00 in 2018 to 3.22 in 2024, a change of 321.9%.


Related Companies

Financial statements for NASDAQ:CVAC last updated on 4/30/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel